Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

DC-STAMP, Syncytin-1, Annexins, S100A4 and Phosphatidylserine in The Cell Fusion Stage of Osteoclastogenesis

Many proteins have been implicated into a multistep process that generates bone-resorbing multinucleated osteoclasts. Here, for the first time, we specifically focus on the cell fusion step of this process. To uncouple merger of the cell membranes from pre-fusion stages of osteoclastogenesis, we accumulated ready-to-fuse cells in the presence of a fusion inhibitor lysophosphatidylcholine and then removed it to study synchronized cell fusion. Synchronized fusion depended on a non-apoptotic exposure of phosphatidylserine at the surface of fusion-committed osteoclast precursors that we found to involve DC-STAMP, a known regulator of osteoclastogenesis. Fusion also depended on cell-surface associated phosphatidylserine-binding proteins annexins (A1 and A5 for murine cells and A5 for human cells). In human osteoclasts, annexin A5 and annexin-binding protein S100A4 regulated fusogenic activity of syncytin 1, another protein that we show to be directly involved in the fusion event. Thus, in contrast to fusion processes mediated by a single protein, such as epithelial cell fusion in C. elegans, cell fusion step in osteoclastogenesis is controlled by a coordinated activity of several proteins.